Choose your region

Select the region that best fits your location or preferences.

International

Choose your site language

This setting controls the language of the user interface, including buttons, menus, and all site text. Select your preferred language for the best browsing experience.

Choose your job languages

Select the languages for job listings you want to see. This setting determines which job advertisements will be displayed to you.

Universal Diagnostics S.L.

Seville, Spain

Visit website

About the employer

Universal Diagnostics is a biomedicine start-up focused on the development of leading edge technologies in metabolomics, genetics and bioinformatics, with the mission to develop a blood test for early detection.

HISTORY

Summer 2012

The seed of Universal Diagnostics (UDX) was born at NASA Ames Park, in Mountain View, California, during the summer of 2012. Following SingularityUniversity’s global challenge to impact positively one billion people, two experienced technology entrepreneurs decided to launch together a bio-medicine start-up with the goal of fighting Humanity’s most important enemy: cancer.

On October 2012

The company was officially incorporated in Spain.

The monumental goal of UDX is to develop a test to detect cancer early, when it still can be cured and save millions of lives.

On June 2013

The company closed a seed round of capital from international investors.

During 2013

UDX started a large-scale research metabolomics project for discovering ex-novo biomarkers for different cancers with high incidence and mortality rate in the world.

During 2014

UDX has established alliances and collaborations with international universities, companies, biobanks and hospitals to validate the technology in all races and populations.

Following clinical trials and regulatory approval, UDX will offer tests for the early diagnostics of the most prevalent cancers.

UDX’s first product is a blood-based test for the early detection of colorectal cancer and polyps, the precursor to colorectal cancer.